ATNM
Price:
$1.76
Market Cap:
$54.83M
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple...[Read more]
Industry
Biotechnology
IPO Date
2012-12-27
Stock Exchange
AMEX
Ticker
ATNM
According to Actinium Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -1.17. This represents a change of -74.62% compared to the average of -4.61 of the last 4 quarters.
The mean historical PE Ratio of Actinium Pharmaceuticals, Inc. over the last ten years is -3.92. The current -1.17 PE Ratio has changed 2.89% with respect to the historical average. Over the past ten years (40 quarters), ATNM's PE Ratio was at its highest in in the March 2018 quarter at -1.28. The PE Ratio was at its lowest in in the December 2014 quarter at -9.02.
Average
-3.92
Median
-3.53
Minimum
-8.05
Maximum
-1.50
Discovering the peaks and valleys of Actinium Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 187.15%
Maximum Annual PE Ratio = -1.50
Minimum Annual Increase = -70.26%
Minimum Annual PE Ratio = -8.05
Year | PE Ratio | Change |
---|---|---|
2023 | -2.77 | -65.62% |
2022 | -8.05 | 60.14% |
2021 | -5.03 | 17.08% |
2020 | -4.29 | 187.15% |
2019 | -1.50 | -13.79% |
2018 | -1.73 | 4.20% |
2017 | -1.67 | -4.50% |
2016 | -1.74 | -70.26% |
2015 | -5.86 | -10.21% |
2014 | -6.53 | -47.52% |
The current PE Ratio of Actinium Pharmaceuticals, Inc. (ATNM) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-5.28
5-year avg
-4.33
10-year avg
-3.92
Actinium Pharmaceuticals, Inc.’s PE Ratio is greater than MiNK Therapeutics, Inc. (-1.58), less than Affimed N.V. (-0.58), greater than ImmunoGen, Inc. (-122.93), greater than Adaptimmune Therapeutics plc (-2.90), greater than Sangamo Therapeutics, Inc. (-1.42), greater than Rigel Pharmaceuticals, Inc. (-17.35), less than Fortress Biotech, Inc. (-0.70), less than Reviva Pharmaceuticals Holdings, Inc. (-1.05), greater than CTI BioPharma Corp. (-30.90), greater than Ocuphire Pharma, Inc. (-2.14), greater than Annovis Bio, Inc. (-2.29), greater than Cassava Sciences, Inc. (-77.66), greater than Axsome Therapeutics, Inc. (-13.45), less than Seres Therapeutics, Inc. (-0.75), less than Reviva Pharmaceuticals Holdings, Inc. (-1.05), less than Eyenovia, Inc. (-0.74), less than Cognition Therapeutics, Inc. (-0.61), less than TransCode Therapeutics, Inc. (-0.20), less than Kodiak Sciences Inc. (-1.04), less than Exelixis, Inc. (20.98), less than TG Therapeutics, Inc. (36.85), greater than Viking Therapeutics, Inc. (-70.63), greater than Madrigal Pharmaceuticals, Inc. (-13.89), less than BioXcel Therapeutics, Inc. (-0.24),
Company | PE Ratio | Market cap |
---|---|---|
-1.58 | $28.82M | |
-0.58 | $49.79M | |
-122.93 | $8.73B | |
-2.90 | $204.51M | |
-1.42 | $362.30M | |
-17.35 | $247.56M | |
-0.70 | $47.68M | |
-1.05 | $33.39M | |
-30.90 | $1.20B | |
-2.14 | $31.74M | |
-2.29 | $113.96M | |
-77.66 | $1.24B | |
-13.45 | $4.19B | |
-0.75 | $137.42M | |
-1.05 | $36.43M | |
-0.74 | $44.32M | |
-0.61 | $19.04M | |
-0.20 | $8.89M | |
-1.04 | $205.20M | |
20.98 | $9.79B | |
36.85 | $3.77B | |
-70.63 | $7.04B | |
-13.89 | $7.23B | |
-0.24 | $26.28M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Actinium Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Actinium Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Actinium Pharmaceuticals, Inc.'s PE Ratio?
How is the PE Ratio calculated for Actinium Pharmaceuticals, Inc. (ATNM)?
What is the highest PE Ratio for Actinium Pharmaceuticals, Inc. (ATNM)?
What is the 3-year average PE Ratio for Actinium Pharmaceuticals, Inc. (ATNM)?
What is the 5-year average PE Ratio for Actinium Pharmaceuticals, Inc. (ATNM)?
How does the current PE Ratio for Actinium Pharmaceuticals, Inc. (ATNM) compare to its historical average?